US 11739093
Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors
granted A61PA61P35/00
Quick answer
US patent 11739093 (Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors) held by Revolution Medicines, Inc. expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Revolution Medicines, Inc.
- Grant date
- Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61P, A61P35/00